• MDB Capital highlighted a new PatentVest market analysis mapping 27 global triple-agonist obesity drug programs as competition shifts beyond first-generation GLP-1 therapies.
• Report flagged Eli Lilly’s retatrutide as leading candidate, with efficacy approaching bariatric-surgery-level weight loss.
• Intellectual property positioning emerged as key battleground, with focus moving from receptor discovery toward receptor-ratio engineering, formulations, delivery systems, method-of-use claims.
• China accounted for significant share of triple-agonist development activity, pointing to potential shift in innovation center, future licensing dynamics.
• Analysis suggested some large pharma could hold “latent” IP positions that may shape market structure even without visible clinical programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MDB Capital Holdings LLC published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605081030PRIMZONEFULLFEED9716488) on May 08, 2026, and is solely responsible for the information contained therein.